Form 4: Iovance Biotherapeutics COO Igor Bilinsky Reports Stock Transactions
SEC Form 4 Filing
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On April 15, 2024, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, had 2,812 restricted stock units (RSUs) vest.
- The company withheld 1,427 shares at a price of $11.89 to cover mandatory tax obligations.
- Following these transactions, Bilinsky directly owns 38,026 shares of common stock and 8,439 restricted stock units.
- These remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The vesting of RSUs and subsequent tax withholding have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/14/2022 | Date of grant for the reported Restricted Stock Units |
| 04/15/2024 | Date of RSU vesting and tax withholding. |
| 04/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.